Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    (2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    J&J Showcases Neuropsychiatry Portfolio At Psych Congress
    J&J Showcases Neuropsychiatry Portfolio At Psych Congress

    24 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/johnson--johnson-highlights-innovative-neuropsychiatry-portfolio-and-pipeline-at-psych-congress-302285418.html

    PR NEWSWIRE
    24 Oct 2024
    Share Share
    J&J seeks expanded approval for antidepressant Spravato
    J&J seeks expanded approval for antidepressant Spravato

    22 Jul 2024

    // PRESS RELEASE

    https://www.investor.jnj.com/news/news-details/2024/Johnson--Johnson-seeks-U.S.-FDA-approval-of-SPRAVATO-esketamine-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression/default.aspx

    PRESS RELEASE
    22 Jul 2024
    Share Share
    OptiMed Introduces New Service For Treatment-Resistant Depression
    OptiMed Introduces New Service For Treatment-Resistant Depression

    12 Jun 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=876673&lang=en

    ACCESSWIRE
    12 Jun 2024
    Share Share
    Johnson & Johnson 1Q Results
    Johnson & Johnson 1Q Results

    20 May 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2024-05-20/johnson-amp-johnson-1q-results/?widget=listSection

    CONTRACT PHARMA
    20 May 2024
    Share Share
    Data Suggests SPRAVATO is More Tolerable and Effective Compared to Quetiapine XR
    Data Suggests SPRAVATO is More Tolerable and Effective Compared to Quetiapine XR

    08 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/10/08/2756367/0/en/New-Safety-Data-Suggests-SPRAVATO-Esketamine-Nasal-Spray-is-More-Tolerable-and-Effective-Compared-to-Quetiapine-Extended-Release-XR-in-Adults-with-Treatment-resistant-Major-Depress.html

    GLOBENEWSWIRE
    08 Oct 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Esketamine Hydrochloride
    FDA Confirms Paragraph IV Patent Litigation for Esketamine Hydrochloride

    25 Apr 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-esketamine-hydrochloride-49242.pdf

    FDA
    25 Apr 2023
    Share Share